AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29049935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29049935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (IN-OT)
Number of subjects: 0
Study 27461394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphenopalatine ganglion (SPG) stimulation
Number of subjects: 33
Study 24828035 — intervention group
Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg b.i.d.
Number of subjects: 8442
Study 24828035 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg b.i.d.
Number of subjects: 8442
Study 22825654 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) administered orally prior to FDG-PET in 65 patients
Number of subjects: 130
Study 22825654 — intervention group
Group type: COMPARATOR
Intervention: Control group (65 patients without PPI)
Number of subjects: 130
Study 19936917 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (oral tegafur-uracil) for 2 years
Number of subjects: 1057
Study 19936917 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) for six courses
Number of subjects: 1057
Study 17706404 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 5
Study 17706404 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional radiotherapy (control arm)
Number of subjects: 5
Study 15956984 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine (up to 250 mg/day)
Number of subjects: 48
Study 15956984 — intervention group
Group type: COMPARATOR
Intervention: Risperidone (up to 5 mg/day)
Number of subjects: 48
Study 12385688 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam 200 mg tid for 7 days
Number of subjects: 0
Study 12385688 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam 200 mg bid for 7 days
Number of subjects: 0
Study 12385688 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam 400 mg bid for 3 days
Number of subjects: 0
Study 12385688 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 12385688 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin 400 mg bid for 3 days
Number of subjects: 0
Study 10447316 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha treatment for at least 24 weeks
Number of subjects: 172
Study 10447316 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative qualitative HCV RNA test after 12 weeks of interferon treatment
Number of subjects: 172
Study 10447316 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged treatment with interferon-alpha (> 6 months)
Number of subjects: 172
Study 7839429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose arginine vasopressin (AVP) infusion, n = 11
Number of subjects: 24
Study 7839429 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control), n = 13
Number of subjects: 24
Study 7839429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose arginine vasopressin (AVP) infusion
Number of subjects: 24
Study 2201722 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg with ethanol (0.2‐0.4 g/kg)
Number of subjects: 9
Study 2201722 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg with ethanol (0.2‐0.4 g/kg)
Number of subjects: 9
Study 2201722 — intervention group
Group type: COMPARATOR
Intervention: Ethanol alone (0.2‐0.4 g/kg)
Number of subjects: 9
Study 2201722 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg and Nitrazepam 5 mg with ethanol
Number of subjects: 9
Study 1256966 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects group (high cues)
Number of subjects: 40
Study 1256966 — intervention group
Group type: COMPARATOR
Intervention: Slides group (low cues)
Number of subjects: 40
Study 30445461 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Number of subjects: 24
Study 30445461 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RES)
Number of subjects: 24
Study 30445461 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Exercise (AER) and Resistance Exercise (RES) combined
Number of subjects: 24
Study 28823623 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA®
Number of subjects: 150
Study 28823623 — intervention group
Group type: COMPARATOR
Intervention: J-Tip Needleless Injection System®
Number of subjects: 150
Study 28823623 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 150
Study 25929699 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in women with ischemic heart disease
Number of subjects: 1790
Study 25929699 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in women with LBBB
Number of subjects: 1790
Study 25929699 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D in men with LBBB
Number of subjects: 1790
Study 25929699 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD in ischemic women
Number of subjects: 1790
Study 25929699 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD in nonischemic women
Number of subjects: 1790
Study 25929699 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate shock therapy in women
Number of subjects: 1790
Study 25929699 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate shock therapy in men
Number of subjects: 1790
Study 23761424 — intervention group
Group type: COMPARATOR
Intervention: Maximal voluntary contraction (MVC) in contralesional limb
Number of subjects: 7
Study 23761424 — intervention group
Group type: COMPARATOR
Intervention: Maximal voluntary contraction (MVC) in ipsilesional limb
Number of subjects: 7
Study 23761424 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation deficits
Number of subjects: 7
Study 23761424 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG amplitude deficits
Number of subjects: 7
Study 23761424 — intervention group
Group type: EXPERIMENTAL
Intervention: Antagonist coactivation percentage
Number of subjects: 7
Study 23761424 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle volume
Number of subjects: 7
Study 23761424 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz torque
Number of subjects: 7
Study 23761424 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific torque (50Hz torque/muscle volume)
Number of subjects: 7
Study 22029549 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 25-100 mg (mean final dose = 89.9 mg)
Number of subjects: 147
Study 22029549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 22029549 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment drinking levels
Number of subjects: 147
Study 18284391 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin salve
Number of subjects: 37
Study 18284391 — intervention group
Group type: COMPARATOR
Intervention: Sodium carboxymethylcellulose hydrocolloid polymer treatment
Number of subjects: 37
Study 17175743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 17175743 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 0
Study 17175743 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 12464717 — intervention group
Group type: EXPERIMENTAL
Intervention: Madopar DR
Number of subjects: 20
Study 12464717 — intervention group
Group type: COMPARATOR
Intervention: Madopar HBS
Number of subjects: 20
Study 11115954 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV 200 mg once daily (group A)
Number of subjects: 12
Study 11115954 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV 400 mg once daily (group B)
Number of subjects: 12
Study 11115954 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg (day 1), 400 mg (day 15), 800 mg (day 18), 1200 mg (day 21)
Number of subjects: 12
Study 11115954 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 1200 mg/400 mg RTV
Number of subjects: 12
Study 11115954 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 800 mg/400 mg RTV or 1200 mg/200 mg RTV
Number of subjects: 12
Study 9339786 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized dynamic posturography in suspected malingerers
Number of subjects: 541
Study 9339786 — intervention group
Group type: COMPARATOR
Intervention: Computerized dynamic posturography in normal subjects
Number of subjects: 541
Study 9339786 — intervention group
Group type: COMPARATOR
Intervention: Computerized dynamic posturography in patients with balance disorders
Number of subjects: 541
Study 8456478 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar citrate (HOC) reflush
Number of subjects: 30
Study 8456478 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate‐buffered sucrose (PBS140) reflush
Number of subjects: 30
Study 8456478 — intervention group
Group type: COMPARATOR
Intervention: No Reflush
Number of subjects: 30
Study 8456478 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflushing (both HOC and PBS140)
Number of subjects: 30
Study 8456478 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (HOC, PBS140, No Reflush)
Number of subjects: 30
Study 2420106 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH) continuous infusion (400 micrograms bolus followed by 200 micrograms/hour for 6 hours)
Number of subjects: 35
Study 2420106 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone (TRH)
Number of subjects: 35
Study 2420106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31916578 — intervention group
Group type: EXPERIMENTAL
Intervention: LHW-led educational sessions (smoking cessation intervention)
Number of subjects: 0
Study 31916578 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy living intervention)
Number of subjects: 0
Study 29530838 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider profiles with educational tweets
Number of subjects: 6
Study 29530838 — intervention group
Group type: EXPERIMENTAL
Intervention: Female provider profiles with mixed content
Number of subjects: 6
Study 29530838 — intervention group
Group type: COMPARATOR
Intervention: Male provider profiles with mixed content
Number of subjects: 6
Study 29530838 — intervention group
Group type: EXPERIMENTAL
Intervention: Female provider profiles with only personal content
Number of subjects: 6
Study 29530838 — intervention group
Group type: COMPARATOR
Intervention: Male provider profiles with only personal content
Number of subjects: 6
Study 27630127 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab, bortezomib, and dexamethasone
Number of subjects: 0
Study 27630127 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib plus dexamethasone
Number of subjects: 0
Study 25754845 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 382
Study 25754845 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (no MBP)
Number of subjects: 382
Study 23835819 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach by MMCO staff
Number of subjects: 2240
Study 23835819 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2240
Study 23835819 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outreach (as-treated comparison)
Number of subjects: 2240
Study 23835819 — intervention group
Group type: COMPARATOR
Intervention: Usual care (as-treated comparison)
Number of subjects: 2240
Study 20889343 — intervention group
Group type: EXPERIMENTAL
Intervention: Certainty of direction of perturbation
Number of subjects: 0
Study 20889343 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased supra-postural task constraint (equilibrating a cylinder on the tray)
Number of subjects: 0
Study 20889343 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of certainty and high supra-postural task constraint
Number of subjects: 0
Study 20889343 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation with certainty and increased constraint
Number of subjects: 0
Study 18503589 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 0
Study 16830139 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker stress using a full-field stimulator with white LEDs at a frequency of 37 Hz
Number of subjects: 154
Study 16830139 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicker provocation test
Number of subjects: 154
Study 12762269 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10861335 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (n = 10)
Number of subjects: 19
Study 10861335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 19
Study 10861335 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 19
Study 10861335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10861335 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation and Placebo
Number of subjects: 19
Study 8785030 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra-arterial injection of cisplatin at a dose of 100 mg concomitant with hemodialysis (HD)
Number of subjects: 0
Study 8785030 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intra-arterial injection of cisplatin at doses of 200 or 250 mg concomitant with hemodialysis (HD)
Number of subjects: 0
Study 8785030 — intervention group
Group type: COMPARATOR
Intervention: Local intra-arterial injection of cisplatin (dose not specified) without concomitant hemodialysis (HD)
Number of subjects: 0
Study 8256883 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton
Number of subjects: 8
Study 8256883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 3890473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐affective stress management training (SMT)
Number of subjects: 0
Study 3890473 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30936689 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based disease management (DM)
Number of subjects: 319
Study 30936689 — intervention group
Group type: COMPARATOR
Intervention: Usual management (UM)
Number of subjects: 319
Study 29524467 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-relevant contexts (positive opinions about participants)
Number of subjects: 0
Study 29524467 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive, self-referential contexts with direct gaze
Number of subjects: 0
Study 29524467 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral faces with gaze manipulation (direct and averted)
Number of subjects: 0
Study 29524467 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral faces with contextual sentences (positive or negative)
Number of subjects: 0
Study 27600381 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge intervention provided by a social worker
Number of subjects: 151
Study 27600381 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151
Study 27600381 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge intervention with interdisciplinary meeting of significant network members
Number of subjects: 151
Study 27600381 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge intervention with involuntary index admission
Number of subjects: 151
Study 27600381 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-discharge intervention with high educational degree
Number of subjects: 151
Study 25276418 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 268
Study 25276418 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 268
Study 22577884 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics software
Number of subjects: 48
Study 22577884 — intervention group
Group type: COMPARATOR
Intervention: Caloric tables and mental calculations (Control)
Number of subjects: 48
Study 20924975 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (200 mg daily for 6 months)
Number of subjects: 42
Study 18602960 — intervention group
Group type: EXPERIMENTAL
Intervention: PTL-003 (live, attenuated CS1/CS3 ETEC strain)
Number of subjects: 33
Study 18602960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 18602960 — intervention group
Group type: EXPERIMENTAL
Intervention: PTL-003
Number of subjects: 33
Study 16423097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (academic detailing and direct mailings to patients)
Number of subjects: 9652
Study 11755589 — intervention group
Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Clearfil SE Bond
Number of subjects: 0
Study 11755589 — intervention group
Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Unifil Bond
Number of subjects: 0
Study 11755589 — intervention group
Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Prompt L-Pop
Number of subjects: 0
Study 11755589 — intervention group
Group type: EXPERIMENTAL
Intervention: Load cycling (90N for 5000 cycles) with Single Bond
Number of subjects: 0
Study 11755589 — intervention group
Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Clearfil SE Bond
Number of subjects: 0
Study 11755589 — intervention group
Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Unifil Bond
Number of subjects: 0
Study 11755589 — intervention group
Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Prompt L-Pop
Number of subjects: 0
Study 11755589 — intervention group
Group type: COMPARATOR
Intervention: Non-load cycling (control group) with Single Bond
Number of subjects: 0
Study 10691065 — intervention group
Group type: COMPARATOR
Intervention: Information brochure
Number of subjects: 10048
Study 10691065 — intervention group
Group type: COMPARATOR
Intervention: $2 cash incentive
Number of subjects: 10048
Study 10691065 — intervention group
Group type: COMPARATOR
Intervention: $5 cash incentive
Number of subjects: 10048
Study 10691065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 10048
Study 9062854 — intervention group
Group type: EXPERIMENTAL
Intervention: SFSP2
Number of subjects: 21
Study 9062854 — intervention group
Group type: EXPERIMENTAL
Intervention: SFSP1
Number of subjects: 21
Study 9062854 — intervention group
Group type: EXPERIMENTAL
Intervention: G
Number of subjects: 21
Study 9062854 — intervention group
Group type: EXPERIMENTAL
Intervention: SF1
Number of subjects: 21
Study 9062854 — intervention group
Group type: EXPERIMENTAL
Intervention: SF2
Number of subjects: 21
Study 9062854 — intervention group
Group type: COMPARATOR
Intervention: C (NaF toothpaste)
Number of subjects: 21
Study 9062854 — intervention group
Group type: COMPARATOR
Intervention: S (saline)
Number of subjects: 21
Study 3015041 — intervention group
Group type: EXPERIMENTAL
Intervention: COM-ANV therapy
Number of subjects: 39
Study 3015041 — intervention group
Group type: EXPERIMENTAL
Intervention: ANV-COM therapy
Number of subjects: 39
Study 3015041 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Disease (LD)
Number of subjects: 39
Study 3015041 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive Disease (ED)
Number of subjects: 39
Study 3015041 — intervention group
Group type: EXPERIMENTAL
Intervention: ANV therapy
Number of subjects: 39
Study 29532784 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Therapy (FT)
Number of subjects: 832
Study 29532784 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 832
Study 27347788 — intervention group
Group type: EXPERIMENTAL
Intervention: TRANSITECH (2 tablets daily for 10 days)
Number of subjects: 100
Study 23317087 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared attention with similar others
Number of subjects: 0
Study 23317087 — intervention group
Group type: COMPARATOR
Intervention: Viewing the same object with dissimilar others
Number of subjects: 0
Study 23317087 — intervention group
Group type: COMPARATOR
Intervention: Viewing a different object with similar others
Number of subjects: 0
Study 23317087 — intervention group
Group type: COMPARATOR
Intervention: Viewing a different object with different others
Number of subjects: 0
Study 23317087 — intervention group
Group type: COMPARATOR
Intervention: Viewing the object alone with no others present
Number of subjects: 0
Study 23317087 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared attention condition
Number of subjects: 0
Study 22244707 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 10mg t.i.d.
Number of subjects: 24
Study 22244707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 20418370 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium 18 microg/d
Number of subjects: 19
Study 20418370 — intervention group
Group type: EXPERIMENTAL
Intervention: budesonide/formoterol 200/6 2 puffs bid
Number of subjects: 19
Study 20418370 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 18922425 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion (0.2 microg/kg/min) for 24 hours
Number of subjects: 24
Study 18922425 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 24
Study 18922425 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan infusion
Number of subjects: 24
Study 15618526 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment group
Number of subjects: 0
Study 15618526 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 12814378 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (20 Hz)
Number of subjects: 12
Study 12814378 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 12
Study 12814378 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS (5 consecutive sessions)
Number of subjects: 12
Study 12814378 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 12
Study 12814378 — intervention group
Group type: COMPARATOR
Intervention: Real rTMS and Sham rTMS
Number of subjects: 12
Study 10567289 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic insertion of an implantable cardioverter-defibrillator
Number of subjects: 900
Study 10567289 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative symptomatic heart failure (NYHA class I to IV)
Number of subjects: 900
Study 10567289 — intervention group
Group type: EXPERIMENTAL
Intervention: Reoperation
Number of subjects: 900
Study 10567289 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 900